Vantage logo

Are all new sales created equal? 

Pipeline projects are forecast to contribute a substantial proportion of future sales at Abbvie and Lilly, though the same cannot be said for all big drug developers.

Vantage logo

Pharma bends on US pricing debate

Disclosing prices to consumers looks like a fait accompli, although the details are still being debated. Icer, meanwhile, could open the door to biopharma’s early…

Vantage logo

Amarin lands the catch of a lifetime

The topline result from Amarin’s Reduce-It trial has smashed expectations, delighting shareholders and framing Vascepa as a potentially practice-changing product.